Juha joined Kallyope in September 2019 as Chief Business Officer. Juha was formerly Senior Director, Business Development and R&D Strategy at Regeneron Pharmaceuticals. While at Regeneron, he focused on deals with platform technology companies such as Alnylam Pharmaceuticals, bluebird bio, and Intellia Therapeutics, resulting in broad R&D collaborations. In addition, he oversaw two of Regeneron’s strategic collaborations from their start, both of which resulted in the discovery of a drug candidate currently in IND-enabling studies. Juha began his career as a neuroscientist, publishing studies in leading journals including Nature and Neuron. He then launched his business career as a management consultant with Accenture, serving clients in the health care industry. He received his M.D., Ph.D. from the University of Helsinki, completed post-doctoral training at Yale, and subsequently received an MBA from the MIT Sloan School of Management.